drugset
drugset / Trial / NCT04154501

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

NCT04154501 ↗

Phase 1 Completed 68 enrolled Centrexion Therapeutics
RandomizedCrossoverTriple-blindTreatment

Summary

A Phase 1 double-blind, placebo-controlled, randomized single ascending dose incorporating an open-label, 2-period crossover, food effect cohort.

Timeline

Start
2018-12-04
Primary completion
2019-08-21
Completion
2019-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTX-6016 Unknown 25 mg Oral
Subject CNTX-6016 Unknown 50 mg Oral
Subject CNTX-6016 Unknown 100 mg Oral
Subject CNTX-6016 Unknown 300 mg Oral
Subject CNTX-6016 Unknown 450 mg Oral
Subject CNTX-6016 Unknown 600 mg Oral
Subject CNTX-6016 Unknown 800 mg Oral
Subject CNTX-6016 Unknown 1000 mg Oral

Indications

chronic pain syndrome